FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125116249> ?p ?o ?g. }

• W2125116249 endingPage "271" @default.
• W2125116249 startingPage "267" @default.
• W2125116249 abstract "Abstract. Purpose: To compare the intermediate‐term efficacy of 5‐fluorouracil (5‐FU) and Mitomycin C (MMC) as adjunctive antimetabolites in neovascular glaucoma (NVG) filtration surgery. Methods: Forty consecutive eyes of 40 patients with NVG refractory to medical therapy were randomized to receive antimetabolite‐augmented trabeculectomy. Eighteen eyes received postoperative 5‐FU (5‐FU group) and 22 eyes received intraoperative, low‐dose (0.2 mg/ml) MMC for 2 mins (MMC group). The main outcome measure was intraocular pressure (IOP). Surgical success was defined as IOP < 21 mmHg with topical treatment (qualified success) or without topical treatment (complete success). Surgical failure was defined as IOP ≥ 21 mmHg, despite postoperative topical treatment, and by postoperative blindness. Results: The mean follow‐up period was 35.8 ± 22.6 months in the 5‐FU group and 18.6 ± 17.2 months in the MMC group. This difference was not significant. Mean IOP decreased from 40.4 ± 10.3 mmHg to 14.7 ± 3.4 mmHg (p < 0.0001) in the 5‐FU group and from 42 ± 11.3 mmHg to 22.9 ± 13.3 mmHg (p = 0.0006) in the MMC group; however, the difference between the 5‐FU and MMC groups was not significant at any point. The success rate in the 5‐FU group was 55.5% (44.4% complete, 11.1% qualified), compared with 54.5% (9.1% complete, 45.4% qualified) in the MMC group. This difference was not significant. Conclusions: The percentage of patients who achieved postoperative IOP < 21 mmHg was similar in both groups, although a larger proportion of patients treated with MMC‐augmented trabeculectomy required topical treatment in comparison with the 5‐FU group." @default.
• W2125116249 created "2016-06-24" @default.
• W2125116249 creator A5002371249 @default.
• W2125116249 creator A5010828640 @default.
• W2125116249 creator A5018593082 @default.
• W2125116249 creator A5025053503 @default.
• W2125116249 creator A5044113577 @default.
• W2125116249 creator A5069086322 @default.
• W2125116249 date "2006-12-11" @default.
• W2125116249 modified "2023-10-16" @default.
• W2125116249 title "The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up" @default.
• W2125116249 cites W15357752 @default.
• W2125116249 cites W1579337148 @default.
• W2125116249 cites W1965515078 @default.
• W2125116249 cites W1973265611 @default.
• W2125116249 cites W1977149291 @default.
• W2125116249 cites W1982498576 @default.
• W2125116249 cites W1986767996 @default.
• W2125116249 cites W1994178065 @default.
• W2125116249 cites W2006693614 @default.
• W2125116249 cites W2008507018 @default.
• W2125116249 cites W2014726518 @default.
• W2125116249 cites W2019595066 @default.
• W2125116249 cites W2027942320 @default.
• W2125116249 cites W2029997539 @default.
• W2125116249 cites W2037099849 @default.
• W2125116249 cites W2039859890 @default.
• W2125116249 cites W2057068274 @default.
• W2125116249 cites W2072198307 @default.
• W2125116249 cites W2076487688 @default.
• W2125116249 cites W2078650445 @default.
• W2125116249 cites W2090482111 @default.
• W2125116249 cites W2091728997 @default.
• W2125116249 cites W2419663418 @default.
• W2125116249 doi "https://doi.org/10.1111/j.1600-0420.2006.00810.x" @default.
• W2125116249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17488455" @default.
• W2125116249 hasPublicationYear "2006" @default.
• W2125116249 type Work @default.
• W2125116249 sameAs 2125116249 @default.
• W2125116249 citedByCount "46" @default.
• W2125116249 countsByYear W21251162492012 @default.
• W2125116249 countsByYear W21251162492013 @default.
• W2125116249 countsByYear W21251162492014 @default.
• W2125116249 countsByYear W21251162492015 @default.
• W2125116249 countsByYear W21251162492016 @default.
• W2125116249 countsByYear W21251162492017 @default.
• W2125116249 countsByYear W21251162492019 @default.
• W2125116249 countsByYear W21251162492020 @default.
• W2125116249 countsByYear W21251162492021 @default.
• W2125116249 countsByYear W21251162492022 @default.
• W2125116249 countsByYear W21251162492023 @default.
• W2125116249 crossrefType "journal-article" @default.
• W2125116249 hasAuthorship W2125116249A5002371249 @default.
• W2125116249 hasAuthorship W2125116249A5010828640 @default.
• W2125116249 hasAuthorship W2125116249A5018593082 @default.
• W2125116249 hasAuthorship W2125116249A5025053503 @default.
• W2125116249 hasAuthorship W2125116249A5044113577 @default.
• W2125116249 hasAuthorship W2125116249A5069086322 @default.
• W2125116249 hasBestOaLocation W21251162491 @default.
• W2125116249 hasConcept C118487528 @default.
• W2125116249 hasConcept C121332964 @default.
• W2125116249 hasConcept C134018914 @default.
• W2125116249 hasConcept C141071460 @default.
• W2125116249 hasConcept C142424586 @default.
• W2125116249 hasConcept C2776694085 @default.
• W2125116249 hasConcept C2777824320 @default.
• W2125116249 hasConcept C2778397455 @default.
• W2125116249 hasConcept C2778527774 @default.
• W2125116249 hasConcept C2779338040 @default.
• W2125116249 hasConcept C2779829184 @default.
• W2125116249 hasConcept C2780456651 @default.
• W2125116249 hasConcept C2781092963 @default.
• W2125116249 hasConcept C3020578304 @default.
• W2125116249 hasConcept C42219234 @default.
• W2125116249 hasConcept C555293320 @default.
• W2125116249 hasConcept C71924100 @default.
• W2125116249 hasConcept C87355193 @default.
• W2125116249 hasConceptScore W2125116249C118487528 @default.
• W2125116249 hasConceptScore W2125116249C121332964 @default.
• W2125116249 hasConceptScore W2125116249C134018914 @default.
• W2125116249 hasConceptScore W2125116249C141071460 @default.
• W2125116249 hasConceptScore W2125116249C142424586 @default.
• W2125116249 hasConceptScore W2125116249C2776694085 @default.
• W2125116249 hasConceptScore W2125116249C2777824320 @default.
• W2125116249 hasConceptScore W2125116249C2778397455 @default.
• W2125116249 hasConceptScore W2125116249C2778527774 @default.
• W2125116249 hasConceptScore W2125116249C2779338040 @default.
• W2125116249 hasConceptScore W2125116249C2779829184 @default.
• W2125116249 hasConceptScore W2125116249C2780456651 @default.
• W2125116249 hasConceptScore W2125116249C2781092963 @default.
• W2125116249 hasConceptScore W2125116249C3020578304 @default.
• W2125116249 hasConceptScore W2125116249C42219234 @default.
• W2125116249 hasConceptScore W2125116249C555293320 @default.
• W2125116249 hasConceptScore W2125116249C71924100 @default.
• W2125116249 hasConceptScore W2125116249C87355193 @default.
• W2125116249 hasIssue "3" @default.
• W2125116249 hasLocation W21251162491 @default.
• W2125116249 hasLocation W21251162492 @default.

• next